Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMH1BN4)

Drug Name
ISOLOXAPINE Drug Info
Synonyms
ISOLOXAPINE; CHEMBL7828; 8-Chloro-11-(4-methyl-piperazin-1-yl)-dibenzo[b,f][1,4]oxazepine; SCHEMBL2738975; AWHNHDGHHNGACT-UHFFFAOYSA-N; BDBM50028980; LS-61561; 8-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine; 3-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10381810
TTD Drug ID
DMH1BN4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Dopamine D3 receptor (D3R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cariprazine DMJYDVK Bipolar disorder 6A60 Approved [2]
Pramipexole DMNMW9R Parkinson disease 8A00.0 Approved [3]
Ropinirole DMA6S1D Parkinson disease 8A00.0 Approved [3]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [4]
P2B-001 DM9PVHX Parkinson disease 8A00.0 Phase 3 [5]
RP5063 DMKUE8O Schizophrenia 6A20 Phase 2 [6]
ONC201 DMM5SCF Endometrial cancer 2C76 Phase 2 [7]
TAK-906 DMBQD9H Diabetic gastroparesis DA41.00 Phase 2 [8]
GSK598809 DMGU05N Drug abuse 6C4G.1Z Phase 2 [9]
GSK618334 DMJPXZ4 Drug abuse 6C4G.1Z Phase 1 [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Muscarinic acetylcholine receptor M4 (CHRM4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ACECLIDINE DMOLNCZ Glaucoma/ocular hypertension 9C61 Approved [10]
Methacholine Chloride DMGS4QH Asthma CA23 Approved [11]
Tropicamide DM1D90W Mydriasis LA11.62 Approved [12]
Diphenidol DMHPWOM Nausea MD90 Approved [13]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G Discovery agent N.A. Investigative [14]
A-987306 DMU34BK Discovery agent N.A. Investigative [15]
ISOCLOZAPINE DM52CPU Discovery agent N.A. Investigative [16]
FLUMEZAPINE DMW0HOG Discovery agent N.A. Investigative [17]
Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester DMVEH40 Discovery agent N.A. Investigative [11]
GNF-PF-5618 DMT8VUS Discovery agent N.A. Investigative [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Dopamine D1 receptor (D1R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Phenyltoloxamine DMKAEQW Allergy 4A80-4A85 Approved [19]
Pergolide DM14MAE Parkinson disease 8A00.0 Approved [3]
Methylergonovine DMBEX4O Spontaneous abortion JA00.0 Approved [20]
Fenoldopam DMFAOKP Hypertension BA00-BA04 Approved [21]
Zicronapine DMP8ESD Schizophrenia 6A20 Phase 3 [22]
Ecopipam DMS9R43 Cocaine addiction 6C45.2 Phase 3 [23]
DAS-431 DMM3BPL Dementia 6D80-6D86 Phase 2 [24]
Dihydrexidine DMACPQO Psychotic disorder 6A20-6A25 Phase 1/2 [25]
Lu AF28996 DMY572G Parkinson disease 8A00.0 Phase 1 [26]
BAM-1110 DMPMKUF Parkinson disease 8A00.0 Discontinued in Phase 2 [27]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Dopamine D4 receptor (D4R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Clozapine DMFC71L Schizophrenia 6A20 Approved [3]
Phenyltoloxamine DMKAEQW Allergy 4A80-4A85 Approved [19]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [4]
RP5063 DMKUE8O Schizophrenia 6A20 Phase 2 [6]
L-745,870 DMTGR25 Psychotic disorder 6A20-6A25 Phase 2 [28]
NGD 94-1 DMM1Y8F Schizophrenia 6A20 Phase 1 [29]
ABT-724 DMDQVY4 Erectile dysfunction HA01.1 Discontinued in Phase 2 [30]
Lu-35138 DMQ7A35 Psychotic disorder 6A20-6A25 Discontinued in Phase 2 [31]
NGD-94-4 DMZ9WLO Schizophrenia 6A20 Discontinued in Phase 1 [32]
PD-165167 DMD0GB4 Schizophrenia 6A20 Preclinical [29]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Muscarinic acetylcholine receptor M1 (CHRM1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ACECLIDINE DMOLNCZ Glaucoma/ocular hypertension 9C61 Approved [10]
Fesoterodine fumarate DM13495 Overactive bladder GC50.0 Approved [33]
SMT-D002 DM1I93C Seborrhea ED91.2 Approved [34]
Clidinium DMUMQZ0 Abdominal stomach pain DD91.4 Approved [35]
Trihexyphenidyl DMB19L8 Dystonia 8A02 Approved [36]
Oxyphenonium DMMQHOZ Visceral spasms MD81.4 Approved [37]
Benztropine DMGZOVN Parkinson disease 8A00.0 Approved [38]
Glycopyrrolate DM2M3ZA Anaesthesia 9A78.6 Approved [39]
Pirenzepine DMP6M1N Peptic ulcer DA61 Approved [40]
Cycrimine DM8C43Q Parkinson disease 8A00.0 Approved [41]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Muscarinic acetylcholine receptor M2 (CHRM2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ACECLIDINE DMOLNCZ Glaucoma/ocular hypertension 9C61 Approved [10]
Methacholine Chloride DMGS4QH Asthma CA23 Approved [11]
SMT-D002 DM1I93C Seborrhea ED91.2 Approved [34]
Methylscopolamine DM5VWOB Peptic ulcer DA61 Approved [42]
Gallamine Triethiodide DMPO0MS Stabilize muscle contraction FB3Z Approved [43]
FP-1097 DMC1F2T Urinary incontinence MF50.2 Phase 2 [44]
PSD-506 DMT0KB1 Overactive bladder GC50.0 Discontinued in Phase 2 [45]
Otenzepad DMRXHAC Heart failure BD10-BD13 Discontinued in Phase 2 [46]
SCH-211803 DM92E0W Parkinson disease 8A00.0 Discontinued in Phase 1 [47]
Alvameline DMLN0Y5 Alzheimer disease 8A20 Terminated [48]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Dopamine D5 receptor (D5R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Phenyltoloxamine DMKAEQW Allergy 4A80-4A85 Approved [19]
LE-300 DMGJL16 Schizophrenia 6A20 Preclinical [29]
ZD-3638 DM6M9GC Schizophrenia 6A20 Terminated [29]
GMC-283 DMT1RH6 Schizophrenia 6A20 Terminated [29]
(+/-)-nantenine DM0L3GE Discovery agent N.A. Investigative [49]
ISOCLOZAPINE DM52CPU Discovery agent N.A. Investigative [50]
FLUMEZAPINE DMW0HOG Discovery agent N.A. Investigative [51]
1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine DMOL2Y0 Discovery agent N.A. Investigative [50]
1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine DMD2NXL Discovery agent N.A. Investigative [19]
STEPHOLIDINE DMGMXQC Discovery agent N.A. Investigative [52]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Dopamine D2 receptor (D2R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [53]
Haloperidol DM96SE0 Delirium Approved [54]
Perphenazine DMA4MRX Schizophrenia 6A20 Approved [55]
Perazine DM2AOTZ Psychotic disorder 6A20-6A25 Approved [56]
Domperidone DMBDPY0 Gastrointestinal disease DE2Z Approved [57]
Levodopa DMN3E57 Parkinson disease 8A00.0 Approved [58]
Quetiapine DM1N62C Anorexia nervosa cachexia 6B80 Approved [59]
Pimozide DMW83TP Schizophrenia 6A20 Approved [60]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [61]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [62]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Muscarinic acetylcholine receptor M3 (CHRM3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tolterodine DMSHPW8 Overactive bladder GC50.0 Approved [63]
ACECLIDINE DMOLNCZ Glaucoma/ocular hypertension 9C61 Approved [10]
Tiotropium DMFDC0Q Chronic obstructive pulmonary disease CA22 Approved [64]
Ipratropium DMFQ320 Obstructive lung disease CA22.Z Approved [65]
Darifenacin DMWXLYZ Overactive bladder GC50.0 Approved [66]
Methacholine Chloride DMGS4QH Asthma CA23 Approved [67]
SMT-D002 DM1I93C Seborrhea ED91.2 Approved [34]
Solifenacin DMG592Q Overactive bladder GC50.0 Approved [68]
Methylscopolamine DM5VWOB Peptic ulcer DA61 Approved [69]
Cevimeline DMWSMND Sjogren syndrome 4A43.20 Approved [70]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Muscarinic acetylcholine receptor M5 (CHRM5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Promazine DMZAL7W Acute intermittent hepatic porphyria 5C58.11 Approved [71]
ACECLIDINE DMOLNCZ Glaucoma/ocular hypertension 9C61 Approved [10]
Pilocarpine DMV9ADG Glaucoma/ocular hypertension 9C61 Approved [72]
Anisodine DMNOSWU Central and peripheral nervous disease 8A04-8E7Z Approved [73]
Atropine DMEN6X7 Organophosphate poisoning NE6Z Approved [74]
Propiverine DMUWBIJ Urinary incontinence MF50.2 Approved [75]
Umeclidinium DM4E8O9 Chronic obstructive pulmonary disease CA22 Approved [76]
Cimetropium bromide DMZHPNE Gastric motility disorder DA21 Approved [77]
Butylscopolamine DMZKXB7 Dysmenorrhea GA34.3 Approved [78]
Trospium DMX6RTG Overactive bladder GC50.0 Approved [79]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D1 receptor (D1R) TTZFYLI DRD1_HUMAN Inhibitor [1]
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Inhibitor [1]
Dopamine D3 receptor (D3R) TT4C8EA DRD3_HUMAN Inhibitor [1]
Dopamine D4 receptor (D4R) TTE0A2F DRD4_HUMAN Inhibitor [1]
Dopamine D5 receptor (D5R) TTS2PH3 DRD5_HUMAN Inhibitor [1]
Muscarinic acetylcholine receptor M1 (CHRM1) TTZ9SOR ACM1_HUMAN Inhibitor [1]
Muscarinic acetylcholine receptor M2 (CHRM2) TTYEG6Q ACM2_HUMAN Inhibitor [1]
Muscarinic acetylcholine receptor M3 (CHRM3) TTQ13Z5 ACM3_HUMAN Inhibitor [1]
Muscarinic acetylcholine receptor M4 (CHRM4) TTQ3JTF ACM4_HUMAN Inhibitor [1]
Muscarinic acetylcholine receptor M5 (CHRM5) TTH18TF ACM5_HUMAN Inhibitor [1]

References

1 Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6.
2 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
5 Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18.
9 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
10 Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
11 6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55.
12 The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 rec... Psychopharmacology (Berl). 2007 Oct;194(3):347-59.
13 Diphenidol-related diamines as novel muscarinic M4 receptor antagonists. Bioorg Med Chem Lett. 2008 May 1;18(9):2972-6.
14 Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
15 cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
16 Chloro-substituted, sterically hindered 5,11-dicarbo analogues of clozapine as potential chiral antipsychotic agents. J Med Chem. 1990 Feb;33(2):809-14.
17 Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics. J Med Chem. 1989 Dec;32(12):2573-82.
18 Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. J Nat Prod. 2005 Jul;68(7):1061-5.
19 Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
20 Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20.
21 Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9.
22 Clinical pipeline report, company report or official report of Lundbeck.
23 A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome.Clin Neuropharmacol.2014 Jan-Feb;37(1):26-30.
24 Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16.
25 trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization o... J Med Chem. 2006 Nov 16;49(23):6848-57.
26 Clinical pipeline report, company report or official report of Lundbeck
27 Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinso... J Pharmacol Exp Ther. 1998 Jul;286(1):228-33.
28 Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology (Berl). 2009 Apr;203(2):265-77.
29 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
30 Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci U S A. 2004 April 27; 101(17): 6758-6763.
31 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014237)
32 I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. J Pharmacol Exp Ther. 1997 Aug;282(2):1011-9.
33 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
34 Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
35 Accidental acute clidinium toxicity. Emerg Med J. 2009 Jun;26(6):460.
36 The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic dr... Psychopharmacology (Berl). 2009 Apr;203(2):295-301.
37 Ultraviolet spectroscopic estimation of microenvironments and bitter tastes of oxyphenonium bromide in cyclodextrin solutions. J Pharm Sci. 1999 Aug;88(8):759-62.
38 Formulation and biopharmaceutical evaluation of transdermal patch containing benztropine. Int J Pharm. 2008 Jun 5;357(1-2):55-60.
39 Autonomic cardiovascular control during a novel pharmacologic alternative to ganglionic blockade. Clin Pharmacol Ther. 2008 May;83(5):692-701.
40 Negative crosstalk between M1 and M2 muscarinic autoreceptors involves endogenous adenosine activating A1 receptors at the rat motor endplate. Neurosci Lett. 2009 Aug 14;459(3):127-31.
41 Capillary gas chromatography of trihexyphenidyl, procyclidine and cycrimine in biological fluids. J Chromatogr. 1989 Sep 29;494:135-42.
42 Methylacridinium and its cholinergic properties. Neurotox Res. 2009 Nov;16(4):372-7.
43 Cholinergic regulation of the corpora allata in adult male loreyi leafworm Mythimna loreyi. Arch Insect Biochem Physiol. 2002 Apr;49(4):215-24.
44 Clinical pipeline report, company report or official report of FemmePharma.
45 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
46 Beneficial effect of muscarinic-2 antagonist on dilated cardiomyopathy induced by autoimmune mechanism against muscarinic-2 receptor. J Cardiovasc Pharmacol. 2001 Oct;38 Suppl 1:S43-9.
47 Improving the oral efficacy of CNS drug candidates: discovery of highly orally efficacious piperidinyl piperidine M2 muscarinic receptor antagonists. J Med Chem. 2002 Dec 5;45(25):5415-8.
48 In vivo muscarinic cholinergic mediated effects of Lu 25-109, a M1 agonist and M2/M3 antagonist in vitro. Psychopharmacology (Berl). 1998 Jun;137(3):233-40.
49 Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
50 Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1982 Jul;25(7):855-8.
51 Effects of conformationally restricted 4-piperazinyl-10H-thienobenzodiazepine neuroleptics on central dopaminergic and cholinergic systems. J Med Chem. 1982 Oct;25(10):1133-40.
52 Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities Bioorg Med Chem. 2009 Oct 1;17(19):6898-907.
53 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
54 Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
55 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
56 Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
57 Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
58 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
59 Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
60 [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
61 Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
62 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
63 Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53.
64 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
65 Role of parasympathetic nerves and muscarinic receptors in allergy and asthma.Chem Immunol Allergy.2012;98:48-69.
66 M(1) and M(3) muscarinic receptors are involved in the release of urinary bladder-derived relaxant factor. Pharmacol Res. 2009 May;59(5):300-5.
67 Muscarinic M3-receptors mediate cholinergic synergism of mitogenesis in airway smooth muscle. Am J Respir Cell Mol Biol. 2003 Feb;28(2):257-62.
68 Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout ... Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6.
69 Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1998 Nov;125(5):1088-94.
70 Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline, an M3 muscarinic receptor ... Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G112-G123.
71 Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12.
72 Retinoic acid prevents virus-induced airway hyperreactivity and M2 receptor dysfunction via anti-inflammatory and antiviral effects. Am J Physiol Lung Cell Mol Physiol. 2009 Aug;297(2):L340-6.
73 Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
74 Additive protective effects of donepezil and nicotine against salsolinol-induced cytotoxicity in SH-SY5Y cells. Neurotox Res. 2009 Oct;16(3):194-204.
75 Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8.
76 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7354).
77 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
78 Comparison of pharmacological effects of L- and DL-n-butyl-scopolamine in rat uterus. Yao Xue Xue Bao. 1994;29(1):24-7.
79 Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.